| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca |
2014-002370-36: Glucose Control during glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease Behandeling van hoge bloedsuiker tijdens gebruik van glucocorticoïde medicijnenvoor een exacerbatie COPD |
|
|
| Ongoing | 4 | 46 | Europe | Forxiga, Forxiga | Slotervaart Hospital, AstraZeneca | Glucocorticoid induced hyperglycemia Glucocorticoid geinduceerde hyperglycemie | | | | |
2015-002094-38: The Effect of a SGLT2 inhibitor on glucose and ketone production following insulin wirhdrawal |
|
|
| Ongoing | 4 | 24 | Europe | Dapagliflozin, EMEA/H/C/002322, Tablet, Forxiga | University of Surrey, Astra Zeneca, Diabetes UK | In people who are insulin deficient: i.e have type1 or type 3c diabetes, In people who do not make enough insulin, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2016-005140-41: A study of the acute and chronic effects of dapagliflozin plus saxagliptin addition versus single addition of saxagliptin or dapagliflozin on glucose metabolism in patients with type 2 diabetes poorly controlled with metformin Uno studio sugli effetti acuti e cronici dell¿associazione di saxagliptin con dapagliflozin in rispetto all¿aggiunta del singolo componente sul metabolismo glucidico in pazienti con diabete tipo 2 in scarso controllo in trattamento con metformina |
|
|
| Ongoing | 4 | 45 | Europe | FORXIGA, ONGLYZA, FORXIGA, ONGLYZA, Film-coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE, ONGLYZA - 5 MG-COMPRESSE RIVESTITE CON FILM -USO ORALE-BLISTER NON PERFORATO CALENDARIZZATO (ALU/ALU) 28 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, ASTRAZENECA SPA, Dip. Univ. Medicina clinica e sperimentale Pisa | Patients with type 2 diabetes poorly controlled with metformin Pazienti con diabete tipo 2 in scarso controllo in trattamento con metformina, Patients with type 2 diabetes Pazienti con diabete tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2016-004878-17: The effect of SGLT2 inhibitors in people with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 18 | Europe | Forxiga, EMEA/H/C/002322, Tablet, Forxiga | University of Leicester, Astra Zeneca Ltd | Type 2 diabetes., People with hyperglycaemia related diabetes. | | | | |
2017-005136-41: SGLT-2 Inhibition, Metabolomics and Cardiovascular Disease Inhibición de SGLT-2, Metabolómica y Enfermedad Cardiovascular |
|
|
| Not yet recruiting | 4 | 60 | Europe | Tablet, Forxiga 10 mg | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS), AstraZeneca | Type 2 Diabetes mellitus Diabetes mellitus tipo 2, Type 2 Diabetes (adult diabetes) Diabetes tipo 2 (diabetes del adulto), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2019-004586-41: Dapagliflozin, Exercise Training and physicAl function: the DETA trial. |
|
|
| Ongoing | 4 | 140 | Europe | Forxiga, Not applicable, Coated tablet, Forxiga | University of Leicester, AstraZeneca | Frailty and the preceding 'pre-frail' state in patients with type 2 Diabetes Mellitus., Type 2 Diabetes Mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2019-002046-20: Effects of dapagliflozin inhibition on the mechanisms of cardiac damage in the diabetic patient with HFpEF.-CARDIA-STIFF Efectos de la dapagliflozina sobre los mecanismos de la insuficiencia cardiaca con fracción de eyección preservada del paciente diabético”-CARDIA-STIFF |
|
|
| Not yet recruiting | 4 | 62 | Europe | Coated tablet, Forxiga 10 mg | Fundación para la Innovación en Biomedicina-FIBMED, Instituto de Salud Carlos III, Fundación para la Investigación Biomédica del Hospital Gregorio Marañón-FIBHGM | Patients with Diabetes mellitus type 2 and Heart Failure with preserved Ejection Fraction. pacientes con diabetes de tipo 2 e insuficiencia cardíaca con fracción de eyección preservada, Diabetic patients with Heart failure Pacientes diabéticos con insuficiencia cardíaca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-004557-92: Sodium-glucose cotransporter-2 inhibition and renal oxygenation in type 1 diabetes |
|
|
| Not yet recruiting | 4 | 30 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | Steno Diabetes Center Copenhagen, Novo Nordisk Fonden | Type 1 diabetes, Type 1 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-001247-12: 2-week Dapagliflozin therapy effect on sodium elimination in patients with type 2 diabetes mellitus and renal disease |
|
|
| Not yet recruiting | 4 | 17 | Europe | Tablet, Forxiga | University Medical Center Groningen, University Medical Center Groningen | Type 2 diabetes mellitus (T2DM) with impaired renal function, Type 2 diabetes mellitus with renal disease, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-004929-23: Individual urinary protein decreasing effects of dapagliflozin in a remote clinical trial in patients with type 2 diabetes mellitus and elevated urinary protein concentrations. Individuele effecten van dapagliflozine op de hoeveelheid eiwit in urine in een klinisch onderzoek in de thuissituatie in patiënten met suikerziekte en een verhoogde hoeveelheid eiwit in de urine. |
|
|
| Not yet recruiting | 4 | 20 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | University Medical Center Groningen, University Medical Center Groningen, AstraZeneca, Dutch Kidney Foundation | Patients with type 2 diabetes and albuminuria >20 mg/g (2.26 mg/mmol) Patiënten met type 2 diabetes en albuminurie >20 mg/g (2.26 mg/mmol), Type 2 diabetes Suikerziekte, Diseases [C] - Hormonal diseases [C19] | | | | |
@HOME, NCT06374043: Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. |
|
|
| Completed | 4 | 20 | Europe | Dapagliflozin 10mg Tab, Forxiga, (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, A10BK01, Placebo, Withings BPM Connect, Withings Body+, Hem-Col Capillary Blood Collection Device, MEMS (Medication Electronic Monitoring System) Cap, Questionnaire: participants' perspectives toward remote data collection | University Medical Center Groningen, AstraZeneca | Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, CKD, Proteinuria | 09/22 | 09/22 | | |
2018-003283-31: Effects of 2 Weeks treatment with Dapagliflozin in subjects with an Impaired Glucose Homeostasis on Nocturnal substrate oxidation |
|
|
| Not yet recruiting | 4 | 17 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University, AstraZeneca AB | Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis, Effect of dapagliflozin treatment on the switch between carbohydrate and lipid oxidation during the night, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-003310-39: Effect of the antidiabetic drug dapagliflozin on the coronary function in type 2 diabetic patients. |
|
|
| Not yet recruiting | 4 | 100 | Europe | Tablet, Forxiga | CHU Saint Pierre, Cardiology Department CHU Saint Pierre, Brussels | Coronary macrovascular and microvascular function of type 2 diabetic patients with stable coronary artery disease and acute coronary syndrome (excluding ST elevation myocardial infarction)., Coronary function of type 2 diabetic patients with stable coronary artery disease and acute coronary syndrome (excluding ST elevation myocardial infarction)., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-000995-13: Effects of Dapagliflozin on CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) Effekten af dapagliflozin på hjertets struktur og funktion hos patienter med kronisk nyresygdom |
|
|
| Ongoing | 4 | 222 | Europe | Forxiga, Tablet, Forxiga | Department of Cardiology, Herlev and Gentofte hospital, Novo Nordisk Foundation, Gentofte hospital | Chronic kidney disease Kronisk nyresygdom, Chronic kidney disease Kronisk nyresygdom, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
EVOMETA, NCT04706637: A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin |
|
|
| Not yet recruiting | 4 | 120 | RoW | Evogliptin, Dapagliflozin | Kyung Hee University Hospital at Gangdong, Dong-A ST Co., Ltd. | Bone Diseases, Metabolic, Diabetes Mellitus, Type 2 | 01/22 | 01/23 | | |
2021-005394-66: Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fraction Effetti del Dapagliflozin sulla deformazione cardiaca e sugli esiti clinici nello scompenso cardiaco con frazione di eiezione ridotta e lievemente ridotta |
|
|
| Not yet recruiting | 4 | 88 | Europe | Dapagliflozin, [Dapagliflozin], Film-coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, ASTRAZENECA | heart failure with left ventricular ejection fraction <50% insufficienza cardiaca con frazione di eiezione ventricolare sinistra < 50%, heart failure with reduced or mildly reduced left ventricular ejection fraction insufficienza cardiaca con frazione di eiezione ventricolare sinistra ridotta o moderatamente ridotta, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function |
|
|
| Recruiting | 4 | 17 | Canada | Dapagliflozin 10 MG [Farxiga] | George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals | Diabetes Mellitus, Type 2, Impaired Renal Function | 03/22 | 04/22 | | |
2019-000979-16: Dapagliflozin effect in the reduction of abdominal fat layers in type 2 diabetic patients. Efecto de dapagliflozina en la reducción de la grasa abdominal en pacientes diabéticos tipo 2. |
|
|
| Not yet recruiting | 4 | 88 | Europe | Tablet, Metformin, Dapagliflozin | Dr. Guillem Cuatrecasas - CPEN S.L., AstraZeneca Farmacéutica Spain, S.A. | Abdominal fat layers in type 2 diabetic patients Reducción de la capa de grasa omental en pacientes con diabetes tipo 2, Abdominal fat layers in type 2 diabetic patients Reducción de la capa de grasa omental en pacientes con diabetes tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT02981966: Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects |
|
|
| Completed | 4 | 32 | US | Dapagliflozin, Farxiga, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 04/22 | 05/23 | | |
NCT02981069: Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM |
|
|
| Completed | 4 | 90 | US | Dapagliflozin, Farxiga, Exenatide, Byetta, Bydureon, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/22 | 03/23 | | |
2022-002428-10: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS? |
|
|
| Ongoing | 4 | 330 | Europe | dapagliflozin, Tablet, Forxiga (dapagliflozin) | Oslo Univeristy Hospital - Rikshospitalet, AstraZeneca | Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and vascular pathology. As secondary endpoints, we will look at the effect of visceral fat accumulation and blood pressure., Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on kidney graft survival and preserved function of the kidney., Diseases [C] - Symptoms and general pathology [C23] | | | | |
2022-002453-25: Study of the effects of sodium-glucose cotransporter 2 inhibitors on kidney function in patients undergoing cardiac surgery Studie naar effect van sodium-glucose cotransporter-2 inhibitoren op nierfunctie in patiënten die een hartoperatie ondergaan |
|
|
| Ongoing | 4 | 784 | Europe | Film-coated tablet, Forxiga | Amsterdam UMC, Netherlands Organisation for Health Research and Development | Cardiac Surgery-Associated Acute Kidney Injury cardiochirurgie geassocieerde nierinsufficiëntie, Kidney failure following cardiac surgery Nierschade optredend na hartoperaties, Diseases [C] - Symptoms and general pathology [C23] | | | | |
DAPA-AF, NCT04792190: Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation |
|
|
| Completed | 4 | 25 | US | dapagliflozin, Placebo | University of Rochester, AstraZeneca | Atrial Fibrillation | 03/23 | 06/23 | | |
NCT02616666 / 2015-001873-42: A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients |
|
|
| Active, not recruiting | 4 | 632 | Europe | Dapagliflozin, FORXIGA, Standard of Care | University of Liverpool, AstraZeneca, Clinical Practice Research Datalink | Type 2 Diabetes Mellitus | 07/24 | 07/24 | | |
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration |
|
|
| Completed | 4 | 72 | US | Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
| Recruiting | 4 | 80 | Europe | Dapagliflozin, Forxiga, Placebo | Frank Ruschitzka, AstraZeneca | Heart Failure，Congestive | 12/24 | 12/24 | | |
NCT04363697: Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) |
|
|
| Recruiting | 4 | 2400 | US | Dapagliflozin, Placebo | The TIMI Study Group, AstraZeneca, Worldwide Clinical Trials | Acute Heart Failure, Heart Failure | 01/24 | 03/24 | | |
EPIDOTE, NCT03499704: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy |
|
|
| Active, not recruiting | 4 | 133 | RoW | Pioglitazone + Alogliptin, SYR-322-4833, Alogliptin, Metformin, Dapagliflozin | Celltrion Pharm, Inc. | Diabetes Mellitus, Type 2 | 01/24 | 06/24 | | |
NCT05743907: Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control |
|
|
| Recruiting | 4 | 232 | RoW | DA-2811, Forxiga | Dong-A ST Co., Ltd. | Diabetes Mellitus | 12/24 | 12/24 | | |
DAPAMICRO, NCT05392959: Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients |
|
|
| Terminated | 4 | 4 | Europe | Dapagliflozin 10 mg Tab, Forxiga®, Placebo | Centre Hospitalier Universitaire Saint Pierre, AstraZeneca | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
| Enrolling by invitation | 4 | 29 | US | Dapagliflozin 10mg Tab | Johns Hopkins University, University of California, Los Angeles, Brett Boyer Foundation, AstraZeneca | Heart Failure | 11/24 | 06/25 | | |
NCT06054035: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes |
|
|
| Recruiting | 4 | 182 | Europe | Dapagliflozin (Forxiga®), Placebo matching Dapaglifolzin, Lifestyle Intervention | University Hospital Tuebingen, German Federal Ministry of Education and Research, German Center for Diabetes Research, AstraZeneca | Type2diabetes, PreDiabetes, Renal Failure | 03/26 | 12/26 | | |
2022-001262-35: Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 Dapagliflozin és hatása a szív- és érrendszeri eseményekre akut szívelégtelenségnél – myokardiális infarktus trombolízisénél 68 |
|
|
| Ongoing | 3/4 | 2400 | Europe | Dapagliflozin, Film-coated tablet | The Brigham and Women's Hospital, Inc., AstraZeneca Pharmaceuticals LP, Brigham and Women's Hospital | The study is evaluating the effect of In-hospital initiation of dapagliflozin in patients who have been stabilized during hospitalization for Acute Heart Failure A vizsgálat során a dapagliflozin kórházban történő elindításának hatását értékelik ki olyan betegeknél, akiket akut szívelégtelenség miatti kórházi kezelés során stabilizáltak., acute heart failure akut szívelégtelenségnél, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2008-004916-12: A 24-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metformin compared with a DPP-4 inhibitor (Sitagliptin) in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone |
|
|
| Ongoing | 3 | 494 | Europe, RoW | Dapagliflozin, Sitagliptin, BMS-512148, A10BH01, Film-coated tablet, Over encapsulated tablet, Januvia, JANUVIA Tablets | AstraZeneca AB | Type 2 Diabetes Mellitus | | | | |
2015-004164-11: Effect of the glucose-lowering drug dapagliflozin on vascular function and blood pressure Effetto dell’antidiabetico orale dapagliflozin sulla funzione vascolare e sulla pressione arteriosa |
|
|
| Ongoing | 3 | 55 | Europe | FORXIGA, ESIDREX, NON DISPONIBILE, Film-coated tablet, Tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE, ESIDREX - 25 MG COMPRESSE 20 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AstraZeneca S.p.A | Arterial hypertension Ipertensione arteriosa, Arterial hypertension Ipertensione arteriosa, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2016-003738-25: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study) Eine 28-wöchige, multizentrische, randomisierte, doppel-blinde, placebo-kontrollierte Studie zur Evaluation der Wirksamkeit von Dapagliflozin und Exenatid in Kombination mit einer hoch-dosierten intensivierten Insulintherapie im Vergleich zu Placebo bei adipösen insulin-resistenten Patienten mit Diabetes mellitus Typ 2 |
|
|
| Ongoing | 3 | 60 | Europe | Powder and solvent for suspension for injection, Film-coated tablet, Bydureon, Forxiga | University Medical Center Hamburg-Eppendorf, AstraZeneca GmbH | Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%) Patienten mit Diabetes mellitus Typ 2 und inadäquater glykämischer Kontrolle (HbA1c ≥ 8.0% und ≤ 11.0%), Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%) Patienten mit Diabetes mellitus Typ 2 und inadäquater glykämischer Kontrolle (HbA1c ≥ 8.0% und ≤ 11.0%), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004709-42: Study to evaluate the effect of dapagliflozin, exenatide and their combination on the loss of protein in urine in patients with type 2 diabetes Studie naar het effect van dapagliflozine, exenatide en de combinatie van beiden op het verlies van eiwit via de urine bij patienten met diabetes type 2 |
|
|
| Ongoing | 3 | 17 | Europe | Forxiga, Bydureon, Film-coated tablet, Powder and solvent for prolonged-release suspension for injection, Forxiga, Bydureon | Martini Hospital, Astra Zeneca, Martini Hospital | Type 2 diabetes Diabetes mellitus type 2, Type 2 diabetes Suikerziekte, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004641-25: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetic and non diabetic Chronic Kideny Disease Uno studio che prevede la rotazione di piú farmaci che riducono l'albuminuria per valutare quale sia il miglior farmaco per il singolo paziente Estudio para evaluar la acción individal de diferentes clases de fármacos sobre la albuminuria en pacientes diabéticos y no diabéticos con enfermedad renal crónica |
|
|
| Ongoing | 3 | 46 | Europe | Dapaglifozin, Eplerenone, [na], Tablet, Forxiga, Eplerenone | University Medical Center Groningen, UNIVERSITY MEDICAL CENTER GRONINGEN, University Medical Center Groningen | Proteinuric Kidney disease Insufficienza Renale Cronica Proteinurica Enfermedad Renal Crónica Proteinúrica, Reduction in kidney function with increasing in protein in the urine Peggioramento della funzione renale con aumento delle proteine nelle urine Deterioro de la función renal con aumento de la proteinuria en orina, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-003442-16: DETERMINE-reduced – Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction |
|
|
| Not yet recruiting | 3 | 300 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | AstraZeneca AB, AstraZeneca AB | Heart Failure Patients with Reduced Ejection Fraction (HFrEF), Heart Failure with reduced pump function to eject blood flow, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT03842267: A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study) |
|
|
| Completed | 3 | 315 | RoW | Gemigliptin 50mg, Gemigliptin Placebo | LG Chem | Diabetes Mellitus, Type 2 | 05/21 | 11/22 | | |
NCT04255238: A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone |
|
|
| Not yet recruiting | 3 | 468 | NA | Gemigliptin 50mg, Zemiglo tab 50mg, Dapagliflozin 10mg, Forxiga tab 10mg | LG Chem | Diabetes Mellitus, Type 2 | 05/22 | 12/22 | | |
2021-005446-15: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease Een placebo gecontroleerde studie om het effect van dapagliflozine op nier- en hartfalen te onderzoeken bij nierpatiënten |
|
|
| Not yet recruiting | 3 | 1500 | Europe | Dapagliflozin, Tablet, Forxiga | University Medical Center Groningen, AstraZeneca, Dutch Kidney Foundation | Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population, Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04885712: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Completed | 3 | 378 | RoW | Metformin≥1000mg, BR3003D, Pioglitazone 15mg, BR3003A-1, Pioglitazone 30 mg, BR3003B-1, Pioglitazone 15mg Placebo, BR3003A-2, Pioglitazone 30mg Placebo, BR3003B-2, Dapagliflozin 10mg, BR3003C | Boryung Pharmaceutical Co., Ltd | Type2 Diabetes | 09/22 | 03/23 | | |
NCT05159882: Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM |
|
|
| Recruiting | 3 | 390 | RoW | THR-1442 and Dapagliflozin placebo, Dapagliflozin 10mg and THR1442 placebo | Newsoara Biopharma Co., Ltd. | T2DM | 09/22 | 09/22 | | |
NCT05226897: Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients |
|
|
| Active, not recruiting | 3 | 256 | RoW | YYC405-T, Metformin≥1000mg, Dapagliflozin 10mg, YYC405-T placebo | Yooyoung Pharmaceutical Co., Ltd. | Type 2 Diabetes | 10/22 | 06/23 | | |
NCT05101135: To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Recruiting | 3 | 256 | RoW | JT-001, JT-001 Placebo | Jeil Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 10/22 | 10/22 | | |
2022-000596-40: Effect of dapagliflozin on blood magnesium levels in patients with low magnesium due to HNF1beta-associated kidney disease Het effect van dapagliflozine op het magnesiumgehalte bij patiënten met een laag magnesium door HNF1beta-geassocieerde nierziekte |
|
|
| Not yet recruiting | 3 | 12 | Europe | Tablet, Forxiga | Radboudumc, Dutch Kidney Foundation, AstraZeneca | Renal hypomagnesemia in ADTKD-HNF1β patients Renale hypomagnesiëmie bij ADTKD-HNF1β patiënten, Low magnesium levels in patients with HNF1beta-associated kidney disease Laag magnesiumgehalte bij patiënten met een HNF1beta geassocieerde nierziekte, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
NCT03199053 / 2015-005042-66: Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old |
|
|
| Completed | 3 | 256 | Europe, Canada, US, RoW | Dapagliflozin, Forxiga, Saxagliptin, Onglyza, Placebo | AstraZeneca | Diabetes Mellitus, Type 2 | 02/23 | 01/24 | | |
| Completed | 3 | 240 | US | Dapagliflozin 10 MG, sodium-glucose cotransporter-2(SGLT2) inhibitors, Protocolized Diuretic Therapy | Vanderbilt University Medical Center, AstraZeneca | Heart Failure, Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
| Completed | 3 | 4017 | Europe | Dapagliflozin, Forxiga TM, Farxiga TM, Placebo | AstraZeneca, Uppsala University | Acute Myocardial Infarction, Heart Failure | 07/23 | 07/23 | | |
| Active, not recruiting | 3 | 380 | Europe, US, RoW | sparsentan, RE-021, irbesartan, Irbesartan Tablets USP, Dapagliflozin | Travere Therapeutics, Inc., Retrophin, Inc. | Immunoglobulin A Nephropathy | 08/23 | 07/26 | | |
NCT05296044: To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Recruiting | 3 | 245 | RoW | JT-003, JT-003 Placebo | Jeil Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 10/23 | 02/24 | | |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin |
|
|
| Active, not recruiting | 3 | 340 | RoW | DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 02/24 | 09/24 | | |
NCT06268873: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. |
|
|
| Recruiting | 3 | 2500 | Europe, Canada, Japan, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat CIN-107, Dapagliflozin in combination with placebo | AstraZeneca | Chronic Kidney Disease and Hypertension | 12/27 | 12/27 | | |
BalanceD-HF, NCT06307652: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function |
|
|
| Recruiting | 3 | 4800 | Europe, Canada, Japan, US, RoW | balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin | AstraZeneca | Heart Failure and Impaired Kidney Function | 06/27 | 06/27 | | |
NCT06415773: Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Recruiting | 3 | 418 | RoW | HTD1801, Berberine Ursodeoxycholate, Dapagliflozin | HighTide Biopharma Pty Ltd, Shenzhen HighTide Biopharmaceutical Ltd. | T2DM (Type 2 Diabetes Mellitus) | 07/25 | 09/25 | | |
COMBINED-HF, NCT06434025: IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency |
|
|
| Not yet recruiting | 3 | 99 | RoW | Iron Carboxymaltose, Ferinject, Dapagliflozin 10mg Tab, Forxiga, Placebo of Iron Carboxymaltose, Saline, Placebo of Dapagliflozin | Hospital de Clinicas de Porto Alegre, Vifor Pharma | Heart Failure, Systolic, Iron Deficiencies | 05/26 | 11/26 | | |
| Recruiting | 3 | 450 | Europe | Dapagliflozin propanediol (FORXIGA™/FARXIGA™1), Placebo comparator | Assistance Publique - Hôpitaux de Paris, AstraZeneca | AMI, STEMI, NSTEMI, Left Ventricular Dysfunction | 01/26 | 01/26 | | |
DÁLIA, NCT05886088: Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 597 | RoW | LID104, Dapagliflozin, Linagliptin | EMS | Type 2 Diabetes Mellitus | 05/26 | 01/27 | | |
NCT05374291: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD |
|
|
| Enrolling by invitation | 3 | 1500 | Europe, RoW | Dapagliflozin 10 mg/day (oral), Forxiga, Placebo | University Medical Center Groningen, AstraZeneca, Dutch Kidney Foundation | Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure, Death | 01/27 | 01/27 | | |
NCT06087835: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) |
|
|
| Recruiting | 3 | 1500 | Europe, Canada, Japan, US, RoW | Zibotentan/Dapagliflozin, Dapagliflozin | AstraZeneca | Chronic Kidney Disease With High Proteinuria | 06/27 | 06/27 | | |
| Recruiting | 2/3 | 34 | Europe | Dapagliflozin 10mg Tab, Placebo | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, AstraZeneca | Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension | 09/24 | 09/24 | | |
| Completed | 2b | 609 | Canada, Japan, US, RoW | MEDI3506, Placebo, Dapagliflozin | AstraZeneca | Diabetic Kidney Disease | 05/23 | 05/23 | | |
| Completed | 2b | 542 | Europe, Canada, Japan, US, RoW | Zibotentan, Dapagliflozin, Placebo | AstraZeneca, AstraZeneca AB | Chronic Kidney Disease | 06/23 | 06/23 | | |
| Completed | 2b | 153 | Europe, Canada, Japan, US, RoW | AZD9977, Dapagliflozin | AstraZeneca | Heart Failure, Chronic Kidney Disease | 09/23 | 09/23 | | |
2017-001454-33: A 24-week study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surgery. Estudio de 24 semanas de duración para evaluar el efecto de la dapagliflozina (10 mg en dosis única diaria) asociada a exenatida (2,0 mg en dosis única semanal) en pacientes con diabetes mellitus tipo 2 candidatos a cirugía bariátrica. |
|
|
| Ongoing | 2 | 56 | Europe | Tablet, Powder and solution for solution for injection, Forxiga, Bydureon | Dr. Albert Lecube Torello, Astra Zeneca | Type 2 Diabetes mellitus Diabetes mellitus tipo 2, Diabetes mellitus Diabetes mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-004835-26: Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubulointerstitial damage in the kidney of patients with chronic kidney disease with or without type 2 diabetes Studio monocentrico, randomizzato, controllato, per valutare gli effetti di un trattamento di sei mesi con farmaci inibitori del trasporto renale del glucosio (SGLT2i) sui marcatori di senescenza, infiammazione e danno tubulo-interstiziale nel rene dei pazienti con malattia renale cronica con o senza diabete tipo 2 |
|
|
| Ongoing | 2 | 38 | Europe | Dapagliflozin, [SGLT2i], Gastro-resistant tablet | IRCCS-A.O.U. SAN MARTINO-IST, AstraZeneca SpA | Chronic Kidney Deseas Insufficienza renale cronica, Chronic Kidney Deseas Malattia renale cronica, Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
2021-000726-10: Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A prospective, randomized, double-blind, placebo-controlled, cross-over study Valutazione degli effetti renali e sistemici a breve termine di Dapagliflozin, in pazienti non diabetici con CKD allo stadio IV a rischio di ESKD per grave insufficienza renale e proteinuria persistente: uno studio prospettico, randomizzato, in doppio cieco, controllato con placebo, con disegno cross-over |
|
|
| Not yet recruiting | 2 | 32 | Europe | dapagliflozin, [dapagliflozin], Film-coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AstraZeneca | Non-diabetic stage IV Chronic Kidney Disease (CKD) Insufficienza renale cronica non diabetica IV stadio, Non-diabetic stage IV Chronic Kidney Disease (CKD) Insufficienza renale cronica non diabetica IV stadio, Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | | | | |
2021-001324-18: A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Elevated Levels of Protein in Urine |
|
|
| Not yet recruiting | 2 | 38 | Europe | zibotentan, Dapagliflozin, ZD4054, Dapagliflozin, Capsule, hard, Tablet, Forxiga | University Medical Center Groningen, Astra Zeneca | Patients with elevated Albuminuria, Patients with protein in the urine, Diseases [C] - Hormonal diseases [C19] | | | | |
STADIA-HFpEF, NCT04475042: Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction |
|
|
| Recruiting | 2 | 26 | Europe | Dapagliflozin, Placebo | Mariëlle Scheffer, AstraZeneca | Heart Failure, Diastolic | 11/21 | 05/22 | | |
2020-004614-35: Trial to investigate the effect of SGLT-2 inhibitor in treating elevated blood glucose after acute abdominal surgery |
|
|
| Not yet recruiting | 2 | 24 | Europe | Capsule, forxiga | Ismail Gögenur, Centre for Surgical Science | Postoperative (stress) hyperglycemia in patients with no known diabetes after acute abdominal surgery, elevated blood glucose after acute abdominal surgery in patients with no history of diabetes, Body processes [G] - Metabolic Phenomena [G03] | | | | |
2020-002263-54: Dose-Response Effect, Efficacy, and Safety of AZD5718 in Reducing Albuminuria in Participants with Proteinuric Chronic Kidney Disease |
|
|
| Not yet recruiting | 2 | 632 | Europe | AZD5718, Dapagliflozin, AZD5718, Dapagliflozin, Tablet, Film-coated tablet, Forxiga | AstraZeneca AB, AstraZeneca AB | Proteinuric Chronic Kidney Disease, A gradual loss of kidney function over time accompanied by the presence of excess proteins in the urine, Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT05025735: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 25 | US | Dapagliflozin 10Mg Tab | Saint Luke's Health System, Novartis Pharmaceuticals | Metastatic Breast Cancer, HER2-negative Breast Cancer | 12/22 | 07/23 | | |
2020-000913-33: Personalized treatment of type 2 diabetes Personanpassad behandling av typ 2-diabetes |
|
|
| Not yet recruiting | 2 | 200 | Europe | Ozempic, Forxiga, Solution for injection in pre-filled pen, Film-coated tablet, Ozempic 0,25 mg solution for injection in prefilled pen, Forxiga 10 mg 98 film-coated tablets, Ozempic 0,5 mg solution for injection in prefilled pen, Ozempic 1,0 mg solution for injection in prefilled pen, Forxiga 10 mg 28 film-coated tablets | University of gothenburg, European Research Council | Type 2 diabetes, Type 2 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
| Not yet recruiting | 2 | 54 | Europe | Dapagliflozin 10Mg Tab, Placebo, impedance cardiography, Applanation tonometry, post-ischemic hyperemia of forearm, haemodynamics parameters | University Hospital, Rouen, AstraZeneca | Renal Insufficiency, Chronic | 12/22 | 03/23 | | |
2021-004073-31: Treating mild kidney failure over 24 weeks in people with or without type 2 diabetes or high blood pressure |
|
|
| Not yet recruiting | 2 | 340 | Europe | dapagliflozin, Tablet, Forxiga | University Medical Center Groningen, AstraZeneca | Microalbuminuria, Mild kidney failure, Diseases [C] - Hormonal diseases [C19] | | | | |
TIMOTHY, NCT05268926: TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension |
|
|
| Terminated | 2 | 9 | Europe | Dapagliflozin 10Mg Tab, Placebo | University Medical Center Groningen, AstraZeneca | Albuminuria | 02/23 | 02/23 | | |
EPIK-B4, NCT04899349: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant |
|
|
| Terminated | 2 | 2 | US, RoW | Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin | Novartis Pharmaceuticals | Breast Cancer | 05/23 | 05/23 | | |
2022-000420-38: Dapagliflozin in patients with Right Heart Failure (Dapa-RHF) |
|
|
| Not yet recruiting | 2 | 26 | Europe | Dapagliflozin, Film-coated tablet, FORXIGA | Universitätsmedizin Göttingen, AstraZeneca GmbH | Right heart failure defined as (criteria a-c must all be fulfilled):a) Reduced right ventricular systolic function or RV strain defined as at least one of the followingb) N-terminal pro-BNP (NT-proBNP) >125 pg/mlc) Clinical signs of right cardiac congestion or need for diuretic therapy to prevent signs of congestion, Dysfunction of the right heart structures (right ventricle, tricuspid valve apparatus and right atrium) resulting in impaired ability of right heart to perfuse lungs at normal central venous pressures, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 2 | 32 | Europe | Dapagliflozin 10Mg Tab, Placebo | Mario Negri Institute for Pharmacological Research, AstraZeneca | Chronic Kidney Diseases | 05/24 | 05/24 | | |
NCT06150924: Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria |
|
|
| Recruiting | 2 | 80 | US | Part A - Lorundrostat QD + Dapaglifozin QD, Part A - Lorundrostat QD, Part B - Lorundrostat QD Open Label | Mineralys Therapeutics Inc. | Chronic Kidney Disease | 10/24 | 01/25 | | |
ZEAL UNLOCK, NCT06269484: A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK |
|
|
| Recruiting | 2 | 66 | Europe, Japan, US, RoW | Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin | AstraZeneca | Liver Cirrhosis | 01/25 | 01/25 | | |
ZODIAC, NCT05570305: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria |
|
|
| Enrolling by invitation | 2 | 38 | Europe, Canada, US | Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan | University Medical Center Groningen, AstraZeneca | Chronic Kidney Diseases | 04/24 | 09/24 | | |
MIRO-CKD, NCT06350123: Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease |
|
|
| Recruiting | 2 | 300 | Europe, Canada, Japan, US, RoW | Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin | AstraZeneca | Chronic Kidney Disease | 01/26 | 01/26 | | |
NCT04956809: Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure |
|
|
| Completed | 2 | 3 | US | Dapagliflozin 10Mg Tab, Placebo | University of Pennsylvania, Amgen | HFrEF | 06/23 | 06/23 | | |
| Recruiting | 2 | 195 | Europe, Canada, US, RoW | Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin | AstraZeneca, AstraZeneca AB | Liver Cirrhosis | 01/25 | 04/25 | | |
| Not yet recruiting | 2 | 334 | NA | GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin, Metformin | George Medicines PTY Limited, Brandon Biocatalyst, The George Institute | Type 2 Diabetes | 09/25 | 09/25 | | |
2020-005842-41: BIOAVAILABILITY STUDY OF DAPAGLIFLOZIN 10 mg FORMULATIONS IN HEALTHY VOLUNTEERS UNDER FED CONDITIONS RAZISKAVA BIOLOŠKE UPORABNOSTI ENEGA POSAMIČNEGA ODMERKA FORMULACIJ DAPAGLIFLOZINA 10 mg, PRI ZDRAVIH PROSTOVOLJCIH PO OBROKU HRANE |
|
|
| Ongoing | 1/2 | 24 | Europe | Test 1: Dapagliflozin 10 mg film-coated tablets, Test 2: Dapagliflozin 10 mg film-coated tablets, Reference : Forxiga 10 mg film coated tablets, NA, Film-coated tablet, Forxiga film coated tablets | KRKA, d.d., Novo mesto, KRKA d.d. | Healthy voluneers Zdravi prostovoljci, NA NA, Not possible to specify | | | | |
MOJAVE, NCT05965934: Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 |
|
|
| Recruiting | 1/2 | 33 | US | Direct Sodium Removal Infusate 2.0, SGLT-2 inhibitor (dapagliflozin) | Sequana Medical N.V. | Heart Failure, Volume Overload | 12/24 | 06/25 | | |
NCT04544319: Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg |
|
|
| Not yet recruiting | 1 | 44 | NA | Zemiglo 50mg and Forxiga 10mg, zemiglo and Forxiga, Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg | LG Chem | T2DM | 03/21 | 07/21 | | |
NCT05105698: Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg |
|
|
| Not yet recruiting | 1 | 28 | NA | gemigliptin and dapagliflozin 50/10 mg film-coated tablet (Fasting), DPP-4 inhibitor and SGLT-2 inhibitor combination, gemigliptin and dapagliflozin 50/10 mg film-coated tablet (fed) | LG Chem | Healthy Volunteers | 02/22 | 09/22 | | |
NCT05429593: A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet |
|
|
| Completed | 1 | 152 | Europe | Semaglutide, Dapagliflozin, Semaglutide/dapagliflozin | Novo Nordisk A/S | Healthy Volunteers | 04/23 | 04/23 | | |
NCT06063109: A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin. |
|
|
| Completed | 1 | 51 | RoW | THP-00101 (Dapagliflozin) 10mg, Forxiga Tab. 10mg, THP-00102 (Telmisartan) 80mg, Micardis Tab. 80mg | THPharm Corp. | Hypertension, Diabetes Mellitus, Type 2 | 11/23 | 11/23 | | |
SAHARA, NCT04882358: Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion |
|
|
| Active, not recruiting | N/A | 24 | RoW | ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM, SGLT2 inhibitor, dapagliflozin | Sequana Medical N.V. | Heart Failure, Volume Overload | 08/22 | 12/24 | | |
NCT06127212: Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets |
|
|
| Completed | N/A | 24 | RoW | Dapagliflozin 10 mg film-coated tablet, Test, Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia, Reference | Dexa Medica Group, PT Equilab International | Healthy | 03/23 | 05/23 | | |
| Recruiting | N/A | 160 | Europe | Dapagliflozin 10 milligrams [Farxiga], Placebo | University of Edinburgh, AstraZeneca, NHS Lothian | Heart Failure, Diabetic Cardiomyopathies | 07/28 | 07/28 | | |
| Completed | N/A | 2682052 | Europe, Japan, US | | AstraZeneca | Chronic Kidney Disease | 09/23 | 09/23 | | |
| Active, not recruiting | N/A | 150 | RoW | Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine | Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull | Diabetes Mellitus Type 2 | 10/23 | 10/24 | | |
OPTIMISE-CKD, NCT06203704: Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients |
|
|
| Recruiting | N/A | 1090 | Europe, RoW | | AstraZeneca | Chronic Kidney Disease (CKD) | 09/25 | 09/25 | | |